NCT03009370

Brief Summary

The purpose of this study is to determine whether ovarian reserve is related to recurrent pregnancy loss

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
86

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2016

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2016

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

December 18, 2016

Completed
17 days until next milestone

First Posted

Study publicly available on registry

January 4, 2017

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2017

Completed
Last Updated

January 4, 2017

Status Verified

December 1, 2016

Enrollment Period

8 months

First QC Date

December 18, 2016

Last Update Submit

December 31, 2016

Conditions

Keywords

Ovarian reserve, pregnancy loss

Outcome Measures

Primary Outcomes (1)

  • The effect of the ovarian reserve on the recurrent pregnancy loss

    Venous blood samples will be taken from the antecubital regions of all patients between 8:00 a.m and 9:00 a.m during the early follicular phase (days 2-4) of the menstrual cycle .Serum samples will be stored at -80C and assayed for FSH,LH,E2 and AMH .FSH levels are analyzed by means of an electrochemiluminescence method .The normal range for FSH is 2.5-10 U/L at the early follicular phase. Serum AMH levels will be measured with the use of a human ELİSA kit . The normal range for this assay is 0.05-1.5 ng/ml.In the same morning that the blood tests are performed , the total number of antral follicles measuring 2-10 mm in diameter are evaluated by the operator.A 7.5 -MHz transvaginal probe is used in all examinations.Data will be analyzed with the use of medcalc.

    up to 6 months

Secondary Outcomes (1)

  • Ovarian reserve tests can be used for the diagnosis of the cause of recurrent pregnancy loss

    up to 6 months

Study Arms (1)

Recurrent miscarriage

RM is defined as three or more pregnancy losses at\< 20 weeks of gestation.

Eligibility Criteria

Age20 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Recurrent miscarriage is defined as three or more pregnancy loss at\<20 weeks of gestation.The women between 20 -40 years old with history of RM are recruited.

You may qualify if:

  • Women with RM between 20-40 years old

You may not qualify if:

  • Anovulation or PCOS
  • Presence of endometrosis by laparoscopy or ultrasonography
  • History of ovarian surgery
  • Tobacco use
  • Systemic chemotherapy
  • Pelvic irradition
  • Genetic abnormalities
  • Irregular menstruel cycle
  • family history of premature ovarian failure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi

Istanbul, 34325, Turkey (Türkiye)

RECRUITING

Related Publications (1)

  • Atasever M, Soyman Z, Demirel E, Gencdal S, Kelekci S. Diminished ovarian reserve: is it a neglected cause in the assessment of recurrent miscarriage? A cohort study. Fertil Steril. 2016 May;105(5):1236-1240. doi: 10.1016/j.fertnstert.2016.01.001. Epub 2016 Jan 21.

MeSH Terms

Conditions

Abortion, Habitual

Condition Hierarchy (Ancestors)

Abortion, SpontaneousPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Gonca Yetkin Yıdırım, MD

    Saglik Bilimleri Universitesi

    STUDY DIRECTOR

Central Study Contacts

Gonca Yetkin Yıldırım, MD

CONTACT

Nadiye Köroğlu, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

December 18, 2016

First Posted

January 4, 2017

Study Start

July 1, 2016

Primary Completion

March 1, 2017

Study Completion

March 1, 2017

Last Updated

January 4, 2017

Record last verified: 2016-12

Locations